Question to the Department for Business, Energy and Industrial Strategy:
To ask Her Majesty's Government, further to the third fine levied upon private equity group Cinven by the Competition and Markets Authority on 3 February for NHS price gouging, what plans they have to set up an independent inquiry into the company’s operations.
The Competition and Markets Authority’s decisions in respect of liothyronine and hydrocortisone tablets are subject to appeals to the Competition Appeal Tribunal. It would not be appropriate for the Government to comment on the matter while these legal proceedings are ongoing.